RecruitingNCT07235059ClinicalTrials.gov record

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Chronic Kidney Disease

Ask WCR about this study Official registry record ↗

THE QUICK READ

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type: Interventional
Phase: Phase 1
Age range: 18 years - 65 years
Sex eligible: All sexes
Healthy volunteers: Accepted
Participants: 112 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

Read the full description

This is a three-part randomized, participant- and investigator blinded, placebo-controlled, multi-center, sequential study: single ascending dose (SAD) in healthy volunteers (HV), SAD in participants with chronic kidney disease (CKD) or diabetic chronic kidney disease (DKD) and multiple ascending dose (MAD) in participants with CKD or DKD.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

Able to provide written informed consent before any assessment is performed.

Part A (HV):

• Healthy male and female participants in good health as determined by past medical history, physical examination, vital signs, 12-lead ECG, and laboratory tests at screening and baseline within the normal range.

Parts B \& C (CKD)

• Male and female participants 18 to 65 years of age.

Exclusion Criteria:

Women of childbearing potential.
Sexually active males unwilling to use contraception.

Part A (HV):

Clinically significant abnormal blood pressure, defined as SBP \<90 mmHg or \>140 mmHg or DBP \<55 mmHg or \>95 mmHg.
Abnormal resting HR, defined as \<45 bpm or \>90 bpm.

Part B \& C (CKD)

History of, or currently active, significant illness or medical disorders including, but not limited to, cancer (except for non-melanoma skin cancer), heart failure NYHA III-IV, heart rhythm abnormalities (e.g., atrial fibrillation, sick sinus syndrome, permanent pacemaker), CKD due to autoimmune disease, kidney transplant, dialysis or any other disease the investigator believes may preclude the participant from participating in the this study.
Clinically significant aortic stenosis or mitral insufficiency as identified via echocardiography.
History of myocardial infarction (MI), stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or transient ischemic attack (TIA).

Other protocol defined inclusion/exclusion criteria may apply.

Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment: Random assignment
Masking: Double masked

Part A: OJR520 dose A1

Participants will receive OJR520 dose level A1.

Drug: OJR520

Part A: OJR520 dose A2

Participants will receive OJR520 dose level A2.

Drug: OJR520

Part A: OJR520 dose A3

Participants will receive OJR520 dose level A3.

Drug: OJR520

Part A: OJR520 dose A4

Participants will receive OJR520 dose level A4.

Drug: OJR520

Part A: OJR520 dose A5

Participants will receive OJR520 dose level A5.

Drug: OJR520

Part A: OJR520 dose A6

Participants will receive OJR520 dose level A6.

Drug: OJR520

Part B: OJR520 dose B1

Participants will receive OJR520 dose level B1.

Drug: OJR520

Part B: OJR520 dose B2

Participants will receive OJR520 dose level B2.

Drug: OJR520

Part B: OJR520 dose B3

Participants will receive OJR520 dose level B3.

Drug: OJR520

Part B: OJR520 dose B4

Participants will receive OJR520 dose level B4.

Drug: OJR520

Part C: OJR520 dose C1

Participants will receive OJR520 dose level C1.

Drug: OJR520

Part C: OJR520 dose C2

Participants will receive OJR520 dose level C2.

Drug: OJR520

Part C: OJR520 dose C3

Participants will receive OJR520 dose level C3.

Drug: OJR520

Part C: OJR520 dose C4

Participants will receive OJR520 dose level C4.

Drug: OJR520

Part A: Placebo

Participants will receive the matching placebo.

Other: Placebo

Part B: Placebo

Participants will receive the matching placebo.

Other: Placebo

Part C: Placebo

Participants will receive the matching placebo.

Other: Placebo

OJR520 DRUG

Participants will receive OJR520 in different dose levels.

Placebo OTHER

Participants will receive OJR520 matching placebo.

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

Time frame: From Day 1 (Part A) until Day 71 (Part C)

Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.